Agenus Inc. reported revenue, including non-cash royalties, of $30.2 million in Q3 2025 and $80.0 million year-to-date, compared to $76.6 million year-to-date in 2024. The company recorded an operating loss of $4.5 million for the quarter and $34.6 million year-to-date, an improvement from a $94.6 million operating loss year-to-date in 2024. Net income for Q3 2025 was $63.9 million, with year-to-date net income of $7.5 million, versus a net loss of $185.5 million year-to-date in 2024. Basic earnings per share were $2.00 for the quarter and $0.37 year-to-date, compared to a loss of $8.65 per share in the previous year. Cash used in operations was $14.7 million in Q3 and $60.6 million year-to-date, down from $129.7 million in 2024. Key business developments included the launch of the global Phase 3 BATTMAN trial, government-funded reimbursed access for botensilimab plus balstilimab in France, and survival data presented at ESMO across more than 400 patients with over five refractory cancers. Additionally, the company announced a $10 million bridge facility agreement with Zydus and the deconsolidation of MiNK, resulting in a $100.9 million gain.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110256353) on November 10, 2025, and is solely responsible for the information contained therein.
Comments